newsimpactscreener logonewsimpactscreener
ArticlesMarket ScreeningsPricingDocsBlogChangelogSign inSign up
newsimpactscreener logonewsimpactscreener
ArticlesMarket ScreeningsPricingDocsBlogChangelogSign inSign up
newsimpactscreener— news connected to markets.
@newsimpactscrnr on X@newsimpactscreener on InstagramBriefingsTermsPrivacy
newsimpactscreener logonewsimpactscreener
ArticlesMarket ScreeningsPricingDocsBlogChangelogSign inSign up
For retail & self-directed investors

Catch market-moving news before it hits the crowd.

Two free tools, no account and no card. Subscribe once and the signals come to you — in your inbox and on Telegram.

Free — no card requiredTelegram & email deliverySee how it works →

Start free in seconds — pick one, or both

Free market screenings

Curated screeners

Platform-run Stage 2 setups, breakouts and fundamentals. Subscribe once; results hit your inbox.

Set up screeningsDownload latest momentum picks (CSV)
or

Your own personal briefing

Daily PDF · pre-open

You choose the exact tickers and tags — we send a daily PDF of just their news, summaries and market impact, an hour before the open. Built around your watchlist, no one else’s.

Build my briefingDownload a sample (PDF)
AI chip demand surgeRate cut expectationsEnergy supply pressureChina EV competitionCloud hyperscaler capexReshoring manufacturingDefense spending outlookConsumer credit stressBiotech regulatory cycleDollar strength impactAI chip demand surgeRate cut expectationsEnergy supply pressureChina EV competitionCloud hyperscaler capex

See it first

Real output, before you sign up

A genuine sample of each free tool — the morning briefing PDF and the latest momentum screening. Download either, no account needed.

news-briefing-Jun 11, 2026.pdfDaily PDF

Sample briefing

Tap to view the PDF

Open full briefing →
Build my briefing

How it works

Three steps, no terminal

  1. 01

    Follow the themes heating up

    Track narratives as they build—AI infrastructure, rate expectations, energy policy—before they become headlines everywhere.

  2. 02

    See which stocks and sectors are most exposed

    Get a clear picture of which companies sit closest to a story so you know where to look, not just what happened.

  3. 03

    Narrow ideas that match how you invest

    Filter by the factors you care about—growth, value, sector, risk—and keep your process consistent without manual spreadsheets.

Why it works

Built for how retail investors actually research

You don't need a desk full of monitors. Follow themes, see exposure, and narrow ideas—before the market has already moved.

Get signals before everyone else does

Cut through endless headlines. See which stories and themes are gaining traction so you know what to read first—without a terminal or a research team.

Link headlines to the stocks you already own

Turn "what's everyone talking about?" into "what might affect the names in my brokerage or IRA?"—before the connection is obvious everywhere else.

A steadier process. Fewer rabbit holes.

Whether you check in daily or on weekends, less doom-scrolling, fewer "what did I miss?" moments, and a shorter path from headline to decision.

What you get

Signal, not noise

Themes, not just tickers

Watch how narratives build over time so you're not reacting to every headline in isolation—or missing the ones that actually matter.

Exposure, in plain terms

Get a clear picture of which companies and industries sit closest to a story—before the market has priced it in.

Screen the way you think

Focus on the factors that matter to you—growth, value, risk, sectors—and keep your process consistent without spreadsheets you maintain by hand.

Free market screenings

Curated screenings, free to subscribe

Platform-managed screenings — Stage 2 setups, technicals, fundamentals — run on a schedule. Subscribe once and the results land in your inbox and Telegram, no setup required.

InsiderAt 07:00 AM, Monday through Friday (America/New_York)

Insider & Congress Activity

Where the "smart money" is trading. Aggregates recently disclosed SEC Form 4 insider trades (executives & directors) and STOCK Act disclosures from the Senate & House, then ranks tickers by how significant the activity is — distinct buyers (a 3+ buyer cluster is the headline signal), dollar size, and recency. Shows net buy/sell tilt with C-level, director and Congress flags. Open-market trades only (option exercises, grants and gifts are filtered out).

View screening →
IPOAt 07:00 AM, Monday through Friday (America/New_York)

IPO Screener

Every NYSE & NASDAQ stock that IPO'd in the last year, run through the same momentum + growth-fundamentals screen as AI Supercycle — trend template (50/150/200-day SMA alignment, slope, 52-week proximity, relative strength) plus increasing EPS and three straight earnings beats. The whole IPO board is shown, ranked by RS, with per-row gate flags. Runs daily before the open.

View screening →

Pricing

Lock in the founder rate.

Price increases every 100 subscribers. Early subscribers lock in their rate forever.

Free to explore until launch. The full platform is free of charge while we're in early access. The rates below only kick in at launch — and founders who sign up now lock theirs in for life.
58 founder spots remaining42 / 100 taken
$9/ month
Save 77%

$99/yr · lock in forever

Real-time screening, locked at this price for life.

  • Real-time news impact screener
  • Full impact score breakdown
  • Sector & theme filters
  • Watchlist alerts
  • 7-day history
Lock in $9/mo

Your price is locked for life. Cancel any time — but once you cancel, the founder rate is gone.

Straight answers

Common questions

Who it's for

Retail and self-directed investors who manage their own accounts—taxable brokerage, IRA, or both—and want news tied to opportunities, not noise.

How it's different

Most screeners start with static filters. News Impact Screener starts with what's happening in the world and shows what it might push on in the market—so you're not the last to know.

Why it helps

What would it mean to catch major news before everyone else? Less scrambling, fewer "I should have seen that coming" moments, and a watchlist you actually understand.

Early access

Not ready to be the last to know?

It seems like you want fast, reliable insight—without digging through hours of news. Join the list and get signals before the market reacts. Built for people who invest their own money and want context, not chaos.

Free. No spam. Takes 30 seconds.

Reshoring manufacturing
Defense spending outlook
Consumer credit stress
Biotech regulatory cycle
Dollar strength impact
PDF
nis-momentum-2026-07-03.csvLive screen
SymbolSectorSub SectorRS Rank
APHTechnologyHardware, Equipme…86
DINOEnergyOil & Gas Refinin…86
GEIndustrialsAerospace & Defen…86
IPSCHealthcareBiotechnology86
PLOWConsumer CyclicalAuto - Parts86
RAMPTechnologySoftware - Infras…86
RBBFinancial ServicesBanks - Regional86
TDFinancial ServicesBanks - Diversifi…86
Open screening →
Set up screeningsCSV
ThematicAt 08:00 AM, Monday through Friday (America/New_York)

AI Supercycle

Momentum + fundamentals across the AI buildout — GPUs, AI memory, semicap, optics, data-center power, and the hyperscalers spending the capex. Ranked by relative strength, flagged for which names clear both gates.

View screening →
Browse all market screenings →

Instagram

Markets, in your feed

Daily regime reads, top-story breakdowns, and watchlist setups — the screener's signal, in 30 seconds a day.

Follow @newsimpactscreener
A fintech you’ve never heard of more than doubled while the market barely moved — and it’s breaking out again.

$SEZL: +135% vs the S&P’s +6%. Buy-now-pay-later, and it’s everywhere now. Profits doubled in a year, 4 straight earnings beats.

Entry 170, target 198. Loses the 50-day, you’re out.

Not advice. But the screener that flagged it 👉 newsimpactscreener.com

A fintech you’ve never heard of more than doubled while the market barely moved — and it’s breaking out again. $SEZL: +135% vs the S&P’s +6%. Buy-now-pay-later, and it’s everywhere now. Profits doubled in a year, 4 straight earnings beats. Entry 170, target 198. Loses the 50-day, you’re out. Not advice. But the screener that flagged it 👉 newsimpactscreener.com

View
A boring factory-parts maker just beat the market 10 to 1 — and it’s coiled to break out again.

$NPO: +70% vs the S&P’s +6%. Makes the seals and coatings that keep factories and chip plants running. Unsexy, essential. Almost 6x normal volume today — biggest day in months.

Not a buy yet. Clears 390 on volume, target 434. Loses the 50-day, you’re out.

Not advice.

A boring factory-parts maker just beat the market 10 to 1 — and it’s coiled to break out again. $NPO: +70% vs the S&P’s +6%. Makes the seals and coatings that keep factories and chip plants running. Unsexy, essential. Almost 6x normal volume today — biggest day in months. Not a buy yet. Clears 390 on volume, target 434. Loses the 50-day, you’re out. Not advice.

View
A “boring” drug stock quietly beat the entire market and it’s one push from breaking out.

$AMRX:
+34% vs the S&P’s +6%.
Profits up 73%.
5 straight earnings beats.
4x volume today.

The level to clear is 17.77.

That’s the whole trade.

Not advice.

A “boring” drug stock quietly beat the entire market and it’s one push from breaking out. $AMRX: +34% vs the S&P’s +6%. Profits up 73%. 5 straight earnings beats. 4x volume today. The level to clear is 17.77. That’s the whole trade. Not advice.

View
When everbody else is buying graphic cards and memory chips, I am buying chain and couches to watch the mayhem unfold 🧌🚀

I shared the $HOFT early breakout 6 days ago on June 16, and today it broke out and I entered.

Follow along to receive the same breakout that I do!

When everbody else is buying graphic cards and memory chips, I am buying chain and couches to watch the mayhem unfold 🧌🚀 I shared the $HOFT early breakout 6 days ago on June 16, and today it broke out and I entered. Follow along to receive the same breakout that I do!

View
Liquidia printed 6× its normal volume into its pivot — RS 97, top 3% of the market.

$LQDA is one of the strongest relative-strength leaders in the entire market right now, and it just did something that's hard to ignore: it traded more than six times its average volume in a single session, pressing right up under a clean pivot at 73.22.

Here's the mechanism. After months of basing, the stock ran roughly 80% in six weeks and is now coiled just 3% under its breakout level — and the volume tells you who's behind it. Up-down volume is nearly 3 to 1, the signature of institutions accumulating, not distributing. The business turned the corner too: Liquidia just flipped from losses to profit, posting 52 cents last quarter and blowing past estimates, with EPS up triple digits year over year.

The plan is mechanical. Entry on a confirmed close above 73.22. Stop at 67.36 — 8% risk. First target 84.94, a clean 2-to-1, with a runner to 90. Size to the stop, never to the excitement.

Now the honest part — and it lives right here, not in the hook. This stock has already run hard, so it's a watch until it actually clears 73.22, not a chase. It's also a biotech, which means news and trial/FDA headlines can gap it in either direction. If it loses the 50-day on volume, the setup is dead, no questions.

If you're still waiting for a leader to look "safe," you'll be paying up for it. The screener that flagged this is at newsimpactscreener.com.

Not financial advice. For education only.

Liquidia printed 6× its normal volume into its pivot — RS 97, top 3% of the market. $LQDA is one of the strongest relative-strength leaders in the entire market right now, and it just did something that's hard to ignore: it traded more than six times its average volume in a single session, pressing right up under a clean pivot at 73.22. Here's the mechanism. After months of basing, the stock ran roughly 80% in six weeks and is now coiled just 3% under its breakout level — and the volume tells you who's behind it. Up-down volume is nearly 3 to 1, the signature of institutions accumulating, not distributing. The business turned the corner too: Liquidia just flipped from losses to profit, posting 52 cents last quarter and blowing past estimates, with EPS up triple digits year over year. The plan is mechanical. Entry on a confirmed close above 73.22. Stop at 67.36 — 8% risk. First target 84.94, a clean 2-to-1, with a runner to 90. Size to the stop, never to the excitement. Now the honest part — and it lives right here, not in the hook. This stock has already run hard, so it's a watch until it actually clears 73.22, not a chase. It's also a biotech, which means news and trial/FDA headlines can gap it in either direction. If it loses the 50-day on volume, the setup is dead, no questions. If you're still waiting for a leader to look "safe," you'll be paying up for it. The screener that flagged this is at newsimpactscreener.com. Not financial advice. For education only.

View